Last year, the highest-performing stock pick across Legacy Research handed subscribers the chance of a 1,282% gain.
It was at our Crisis Investing advisory.
And it came from a little-known and highly controversial sector – psychedelic medicine.
What is psychedelic medicine?
Why is Legacy’s investment expert Teeka Tiwari calling it his “next trillion-dollar trade?”
And how can you profit?
It’s all in your Weekly Pulse video update at the top of the page.
Regards,
Chris Lowe
Editor, The Daily Cut and Legacy Inner Circle
| Click here to access the Legacy Inner Circle archive |
| Not yet a Legacy Inner Circle member? Join here. |
Transcript
Tom Beal: Psychedelic treatment is helping people that are suffering with post-traumatic stress disorder (PTSD), depression, anxiety, anorexia, and a bunch of other medical needs.
But it’s also helping people like you, who are seeking to grow and protect their wealth. And we foresee even a larger spike in this. Wait until you hear some of the figures Chris mentions in our discussion today.
My name is Tom Beal, host of The Weekly Pulse, where we bring to you the biggest wealth-growth story of the week.
I’m here today with the editor of Legacy Inner Circle, Chris Lowe. Chris, how do we begin today’s conversation?
Chris Lowe: Tom this week, we’re going to be sharing a clip of the interview I did with Mike “Zappy” Zapolin for members of our Legacy Inner Circle advisory. Zappy is the newest member of the Legacy Research team. He’s the guy Teeka Tiwari has tapped to hunt down the best opportunities in the psychedelic medicine industry. He’ll be working alongside Teeka in that role for our new Palm Beach Special Opportunities advisory.
We’re going to be hearing from Zappy on this brand-new approach to the biotech industry, basically, and how it offers regular investors the ability to get in at ground floor levels on the next Pfizer and Amgen.
This is a very exciting early-stage market megatrend that I really want to make sure is on our readers’ radars. We’re going to get to that clip of Zappy in a moment.
But first, I want to set the table a little by introducing folks to what the psychedelic medicine industry is all about.
And second, I’ll give you a little bit of background on Zappy and his experience in that industry.
Tom: I’m excited to hear more about this, Chris. I’m not sure if it’s the syndrome where if you buy a red car, you see a red car everywhere, but since you brought it to my attention a few weeks ago, I’m seeing ads in the mainstream more and more about this particular topic… which gets me even more excited about the large opportunity that awaits when it’s more accepted by the mainstream.
So I’m excited to hear what Zappy has to say.
Chris: I think you’re right, Tom. It is starting to break through. But again, it’s still very early on. But you’re right, we’re starting to see it percolate through, which is, as you say, a good thing.
Let’s start at the beginning, for folks who are brand new to this. Psychedelics are a loosely defined group of plant-based drugs that can cause altered thoughts and altered sensory perceptions. That’s just a very basic overview. They include things like LSD, or acid… psilocybin, which is the active compound in magic mushrooms… as well as MDMA, which is the active compound in ecstasy and ketamine, which is another drug that’s used as a street drug.
Now, a lot of these compounds bring with them a lot of heavy cultural baggage, Tom. I mean, not just the 1960s and the counterculture movement with LSD and psilocybin, but actually with modern-day party drugs MDMA and ketamine.
So first things first, this is a controversial topic. It’s a topic that some people won’t like to hear about a lot because of that baggage.
But the reason we’re talking about it at Legacy Research, and the reason Teeka Tiwari is so excited about it, is because these compounds show huge promise in treating a range of debilitating mental health disorders, including post-traumatic stress disorder (PTSD), depression, alcoholism, and even anorexia.
These are issues that kill thousands of people in the U.S. alone every year. And they also bring with them huge costs in terms of lost productivity and the healthcare costs associated with treating these illnesses.
And Tom, this isn’t some pie-in-the-sky thinking. This is something that’s already happening. The Food and Drug Administration (FDA), which is responsible for green-lighting new drugs in the U.S., has granted breakthrough therapy designation to psilocybin for treating something called treatment-resistant depression. As the name suggests, that is depression that isn’t alleviated by the current range of pharmaceutical drugs on offer.
And a year later, in 2019, the FDA went ahead and gave breakthrough therapy designation to psilocybin for treating regular depression.
This is a really big deal, Tom. The FDA only grants breakthrough therapy designation to new drugs where the preliminary clinical trials show that they offer a substantial improvement for a major illness or disease over the therapies that are available now.
So this is a very big deal that the FDA has granted this breakthrough therapy approval for psilocybin. And it shows how mainstream this is becoming, at least when we’re talking about the regulators.
And it isn’t just the FDA, Tom. The Department of Veterans Affairs has also approved psilocybin for the treatment of PTSD.
Tom: And so here at The Weekly Pulse, we’re going to get a preview of the interview you recorded with Zappy. And then the full interview will be inside Legacy Inner Circle on Friday. Is that correct?
Chris: That’s right. But before we get to that clip, just a brief introduction to Zappy. He’s a thought leader in the psychedelic space. He actually started his career on Wall Street, very like Teeka. He became a young vice-president of a major investment bank.
Since then, he’s done all sorts of interesting things. He was in the domain name business. He owned the domain name beer.com. He also owned the domain name diamonds.com.
Then, he was in the legal cannabis industry. He was an active investor there.
And now, he is very much involved in the psychedelics industry. He’s widely thought of as the psychedelics “concierge to the stars.”
He made a documentary along with Michelle Rodriguez, who was the actress in the Fast & Furious series. They went to South America together and accessed psychedelic treatments for Michelle. They made a documentary in 2016 called The Reality of Truth.
And more recently, Zappy made a documentary with Lamar Odom, the NBA star and reality TV star, who became horribly addicted and horribly wracked by anxiety. That’s an amazing story of how Zappy intervened with Lamar using psychedelics, with pretty amazing results.
Zappy is very plugged into this industry. He knows what’s going on. Let’s hear from him on why he’s so excited about psychedelics right now.
Mike “Zappy” Zapolin: It’s a beautiful moment. I mean, for society itself. But for investors, it’s kind of a no-brainer. It’s like Teeka says, we’re early, we know that. So we have that. And now, you just want to be right.
And by right, that means that you have to find situations where you’ve got a good management team, you have a good business opportunity. Those really exist.
Billionaire investors Peter Thiel, Christian Angermayer, these guys are positioning themselves in a big way in this space. You’ve got celebrity investors, people like Kevin O’Leary from Shark Tank, Tim Ferriss. These guys are staking companies right now. I’ve spoken to them personally and had conversations where they say this is going to be the next trillion-dollar industry. And I intend to play in this space. This could be the next Amgen or Pfizer that you’re buying today, as it’s in its infancy.
You don’t have to be a genius. You really just have to be, like Teeka says, early and right. The companies we have in our portfolio are doing great, because these are like those biotech and pharma companies. You can hold these and as soon as rescheduling happens, there’s going to be a huge boost.
As more companies come online, as more things are discovered, the whole market just rises with the tide. Kind of like crypto. There’s a lot of overlap with crypto, in that there’s this kind of misunderstood, new category that is happening, and you don’t want to miss it, but at the same time, you want to buy the right things.
I think the crypto investor and the psychedelic investor – there’s a lot of overlap there because there are people, like the readers, who are thinking for themselves, and these two categories, when you’re thinking for yourself, you’re going to make a fortune.
Tom: That’s why I’m excited. We’re here at The Weekly Pulse to bring the biggest wealth-growth strategies that we see. I’m thankful you’re bringing this to my and The Weekly Pulse viewers’ attention. This is similar to alcohol back in the days of Prohibition. When it was reintroduced, it became a huge industry. This is something that is becoming more mainstream and helping those in need with this alternative, psychedelic treatment.
And then also, how to grow and protect your wealth. That’s what we’re here for at The Weekly Pulse. So thanks for bringing it to our attention.
I think this does have huge potential, and I’m excited to be in on the ground floor, per se, as to where this is going.
Chris: Tom, you’re right. This is awesomely good news for humanity, right? Because as you know, a lot of people suffer from PTSD coming back from conflicts, U.S. service members and members of other military forces. Depression, anxiety, addiction – these are all really terrible afflictions, horrible things to be dealing with.
If the promise of these preliminary clinical trials holds up, this is going to be huge breakthrough news for the mental health industry.
But it’s not just breakthrough news for folks who suffer from one of these mental health issues. It’s also fantastic news for investors.
We’ve been tracking this going back to last year. In 2020, Nick Giambruno, who runs our Crisis Investing service, started writing to his readers about psychedelic medicine stocks. In March 2020, he recommended one company called MindMed (MMED). It’s a Canadian company, a listed company.
And he then put out a sell alert in December. So it was March to December. The gain was 1,282% on that stock because he got in on the ground floor. That was the highest-performing stock recommendation of 2020 across all of Legacy, not including crypto. Some of the crypto recommendations that Teeka and others put out were bigger gainers. But of the stocks recommended across all of Legacy, it was a psychedelic medicine stock that delivered 1,282% gains from March to December.
So this really is something for investors to take seriously. And if Zappy, Teeka, and Nick are right, this is the beginning of a much more profitable megatrend to come.
Tom: Well, I just busted the calculator out and typed in 1,282% times a $1,000 investment. And that would be a $12,820 return from a $1,000 investment. A $10,000 investment would’ve returned $128,200. Wow! I’m excited for this.
And that was the largest buy and sell offer that Legacy Research produced last year. But that’s one of many. And that’s why I’m so happy you’re bringing this to my and The Weekly Pulse viewers’ attention.
And I’m excited to dig into the full interview with Zappy in Legacy Inner Circle on Friday to learn even more. Thank you for bringing this to our attention.
Chris: Thanks, Tom.
| Not yet a Legacy Inner Circle member? Join here. |